



## **DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN®**

**Paris, France – 23 September 2010** – DBV Technologies (DBV), a biotechnology company specializing in innovative products for the diagnosis and the treatment of food allergies, announced today that its unique VIASKIN® delivery system has been granted two US patents. In both cases, the lifetime of the patent has been extended until 2026.

Aspects of both patents (US 7,635,488 and US 7,722,897) are incorporated into DBV Technologies' VIASKIN which delivers allergens compounds to the immune system through intact skin.

DBV Technologies' VIASKIN is the first device especially developed for EPicutaneous ImmunoTherapy (EPIT). VIASKIN enhances hydration of the surface of the skin and allows the diffusion of allergens into the superficial layers, so that they can interact with the skin's immune network in order to desensitize food allergy patients safely without any risk of systemic reactions. VIASKIN is applied on intact skin and is completely non-invasive.

Commenting on the announcement, DBV Technologies' CEO and Co-Founder, Pierre-Henri Benhamou, MD said: "We are delighted to have secured two patents central to our VIASKIN technology, which further strengthen the competitiveness of our core technology and we are delighted this protection has been granted for an extended period. To date VIASKIN is successfully marketed as a diagnostic product but has also shown huge promise as a safe, painless and effective therapy for food allergy desensitization."

DBV Technologies recently announced that its lead product VIASKIN PEANUT has been selected to be evaluated in a Phase II study of peanut allergy desensitization led by the U.S. Consortium of Food Allergy Research (CoFAR) and funded by the National Institutes of Health (NIH).

More information on the US Patents can be found at:

Patent US 7,635,488 (concerned with 'Patches and uses thereof')

<http://www.uspto.gov/web/patents/patog/week51/OG/html/1349-4/US07635488-20091222.html>

Patent US 7,722,897 (concerned with 'Patch for screening and sensitization state of a subject with respect to an allergen and use thereof')

<http://www.uspto.gov/web/patents/patog/week21/OG/html/1354-4/US07722897-20100525.html>

More information about DBV Technologies' Peanut Specific EPIT program can be found at:  
<http://www.dbv-technologies.com/viaskin-peanut.asp>